Boston Medical Center

Dr. Ann McClain Terrell Joins The Goddard School’s Educational Advisory Board

Retrieved on: 
Tuesday, February 6, 2024
Preschool, Education, Multimedia, Milwaukee Public Schools, Research, Intervention, GSL, Father, Goddard School, Yale school, Child, Yale School of Medicine, Pediatrics, Faculty, Cardinal Stritch University, Physician, Boston Medical Center, Psychology, Cal, University, Health, Educational leadership, Student, NAEYC, EAB, Conference, National Association, Nursing

Goddard Systems, LLC (GSL), manager of The Goddard School franchise system, welcomes Dr. Ann McClain Terrell to its Educational Advisory Board (EAB).

Key Points: 
  • Goddard Systems, LLC (GSL), manager of The Goddard School franchise system, welcomes Dr. Ann McClain Terrell to its Educational Advisory Board (EAB).
  • View the full release here: https://www.businesswire.com/news/home/20240206624021/en/
    Dr. Ann McClain Terrell, The Goddard School Educational Advisory Board Member (Photo: Business Wire)
    With five decades of professional experience, Dr. Terrell is one of the nation’s preeminent early childhood education leaders.
  • “On behalf of our entire Goddard team, from our corporate staff to the franchisees and faculty at more than 600 Goddard Schools, I am honored to welcome Dr. Terrell to our Educational Advisory Board,” said Dr. Lauren Loquasto, senior vice president and chief academic officer, GSL.
  • “I admire The Goddard School and its commitment to continuously innovating and evolving to deliver the best educational program to its students,” said Dr. Terrell.

IVI RMA Completes Acquisition of North American Operations of Eugin Group, Including Boston IVF and TRIO

Retrieved on: 
Wednesday, January 31, 2024
Health, General Health, Trio, Parent, IVI, Boston Medical Center, Patient, Dream, Fertility, TRIO, Harvard Medical School, Tufts Medical Center, Acquisition, Reproductive medicine, IVF

IVI RMA, one of the largest reproductive medicine groups in the world, today announced that it has completed the acquisition of North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO.

Key Points: 
  • IVI RMA, one of the largest reproductive medicine groups in the world, today announced that it has completed the acquisition of North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO.
  • In addition, Boston IVF brings multiple academic affiliations, including Harvard Medical School, Dartmouth Hitchcock Medical School, Boston University Medical Center, and Tufts Medical Center, among others.
  • “We are excited to officially welcome Boston IVF, its partner clinics and TRIO to the IVI RMA network,” added Lynn Mason, CEO of IVI RMA America.
  • “Together with IVI RMA, we will continue to pave the way for breakthroughs in fertility care.”

Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, January 4, 2024
Survival, Skinner, Editor-in-chief, Boston Medical Center, Doctor of Philosophy, Research, Rutgers University, Standard of care, AL amyloidosis, International Society, Hematology, Boston University, Daratumumab, Internal medicine, Patient, Journal, BMC, Medical device

LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific Advisory Board.
  • I am excited to join the Nexcella team’s efforts to advance NXC-201, a promising CAR-T in relapsed/refractory AL Amyloidosis," commented Dr. Sanchorawala.
  • "Dr. Sanchorawala joining our scientific advisory board further demonstrates our leadership in relapsed/refractory AL Amyloidosis, where NXC-201 is the only CAR-T in development.
  • Dr. Sanchorawala completed residency at Rutgers Health/New Jersey Medical School and her fellowship in hematology/oncology at Boston University Medical Center.

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, January 4, 2024
Survival, Skinner, Editor-in-chief, Boston Medical Center, Doctor of Philosophy, Research, Rutgers University, Standard of care, AL amyloidosis, International Society, Hematology, Boston University, Daratumumab, Internal medicine, Patient, Journal, BMC

LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
  • I am excited to join the Nexcella team’s efforts to advance NXC-201, a promising CAR-T in relapsed/refractory AL Amyloidosis," commented Dr. Sanchorawala.
  • "Dr. Sanchorawala joining our scientific advisory board further demonstrates our leadership in relapsed/refractory AL Amyloidosis, where NXC-201 is the only CAR-T in development.
  • Dr. Sanchorawala completed residency at Rutgers Health/New Jersey Medical School and her fellowship in hematology/oncology at Boston University Medical Center.

Alzheon CEO Dr. Martin Tolar Awarded Eliška and Zdeněk Strmiska Award from Alzheimer’s Foundation for Significant Contribution Towards Research and Treatment of Alzheimer’s Disease, and Donated Cash Prize to INDRC Institute

Retrieved on: 
Wednesday, January 3, 2024
Research, Neurology, Clinical Trials, Philanthropy, Biotechnology, Health, Pharmaceutical, Foundation, Science, Biology, Knowledge management, Dementia, Motivation, Risk, University, Czech, European, Disease, Environment, MD, Doctor of Philosophy, Commerce, Boston Medical Center, AI, Big data, Charles University, Knowledge, Artificial intelligence, Machine learning, Pathology, Assistant, Patient, Intelligence, Medicine, Therapy, Neuron, Pharmaceutical industry

In addition to supporting research both in the Czech Republic and abroad, the Foundation aims to improve the quality and conditions of local patient care and broaden the scope of care provided.

Key Points: 
  • In addition to supporting research both in the Czech Republic and abroad, the Foundation aims to improve the quality and conditions of local patient care and broaden the scope of care provided.
  • Since 2017, thanks to the generous gift from the Eliška Strmiska, the Alzheimer’s Foundation has given the Eliška and Zdeněk Strmiska Award to someone who has made an outstanding and significant contribution to the research and treatment of Alzheimer’s disease and related neurodegenerative diseases.
  • The winner receives 100,000 Czech crowns as an award for their work to date and as motivation for the coming years.
  • “I am honored to be recognized for this prestigious award and pleased to accept the prize on behalf of the Alzheon team.

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Retrieved on: 
Friday, December 8, 2023
FDA, Health, Stem Cells, Genetics, Pharmaceutical, Biotechnology, Einstein Medical Center Philadelphia, Food, Transplant, CRISPR Therapeutics, Therapy, Sickle cell disease, University of Chicago, Disease, Patient, Section, CRSP, Vertex Pharmaceuticals, The James Cancer Hospital, CRISPR, Committee, Volatile organic compound, Hospital, SCD, Haematopoietic system, Boston Medical Center, Pharmaceutical industry, Nursing, Vertex, Boston

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
  • “CASGEVY’s approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the U.S. As importantly, CASGEVY is a first-in-class treatment that offers the potential of a one-time transformative therapy for eligible patients with sickle cell disease,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.
  • So, this U.S. approval of the first-ever medicine using CRISPR gene editing is breathtaking, and a truly humbling moment for me personally and for the whole organization,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics.
  • The following ATCs are already activated:
    Boston Medical Center in Boston, Mass.

Boston Medical Center to Offer First FDA-Approved Gene Therapy Treatment Program for Sickle Cell Disease

Retrieved on: 
Friday, December 8, 2023
BMC, Safety, Chronic pain, Life, Pulmonology, CRISPR Therapeutics, Therapy, Sickle cell disease, Disease, Risk, Vertex Pharmaceuticals, Clinical trial, Vertex, Patient, Nephrology, End organ damage, FDA, Conditional sentence, DSM-IV codes, CRISPR, Pain, Doctor of Philosophy, Volatile organic compound, SCD, Stroke, Blood, Boston Medical Center, Center of excellence, Pharmaceutical industry, Nursing, MD

BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology. The new therapy leverages the latest advances in medical science to alleviate the severe painful vaso-occlusive crises (VOCs) associated with sickle cell disease, in a long-awaited step toward equity for a disproportionally impacted Black patient population.

Key Points: 
  • BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology.
  • The announcement comes as the FDA today granted approval of this new therapy, jointly developed by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics of Switzerland, along with approval of another cell-based gene therapy for sickle cell disease.
  • BMC is the only hospital in New England to offer the Vertex Pharmaceuticals and CRISPR Therapeutics therapy to eligible adults with sickle cell disease.
  • "Boston Medical Center has a longstanding commitment to providing advanced clinical care to those with sickle cell disease," said Dr. Jean-Antoine Ribeil, MD, PhD, Clinical Director of the Center of Excellence in Sickle Cell Disease at Boston Medical Center and an internationally renowned hematologist who has dedicated his career to the development of gene therapies for patients with sickle cell disease and beta thalassemia.

GoGoGrandparent Launches in Australia, Powered By Uber Health

Retrieved on: 
Wednesday, December 6, 2023
Meal, WIDE, Transport, ModivCare, Smartphone, Disability, Multimedia, Uber, City, Caregiver, Partnership, Freedom, API, Business, Mobile, Economics, Boston Medical Center, Enterprise, Travel, Collaboration, Ridesharing, Nightclub, Go go

CANBERRA, Australia, Dec. 6, 2023 /PRNewswire-PRWeb/ -- GoGoGrandparent, the leading provider of transportation solutions for older adults in North America, today launched their inclusive, on-demand mobility service in Australia, delivered in partnership with Uber Health. Through this collaboration, older adults and people with disabilities in Australia can now call GoGoGrandparent at 13 4628 to book rides with Uber without the need for a smartphone or the Uber app.

Key Points: 
  • Through this collaboration, older adults and people with disabilities in Australia can now call GoGoGrandparent at 13 4628 to book rides with Uber without the need for a smartphone or the Uber app.
  • CANBERRA, Australia, Dec. 6, 2023 /PRNewswire-PRWeb/ -- GoGoGrandparent, the leading provider of transportation solutions for older adults in North America, today launched their inclusive, on-demand mobility service in Australia, delivered in partnership with Uber Health.
  • GoGoGrandparent has completed 1.5 million Uber Health rides in the U.S. since the two companies began working together in 2019.
  • By working directly with on-demand services like Uber, GoGoGrandparent manages the mobility, meals, groceries and home services of their clients.

Black Patients Face Delays in Alzheimer's Diagnosis

Retrieved on: 
Monday, November 27, 2023
Radiology, CTS, Health, RSNA, Brain, Research, Safety, Deficit spending, Head, Risk, Disease, Hispanic, Insurance, Patient, Multimedia, Neuroimaging, Neoplasm, Dementia, Newsroom, Bleeding, Diagnosis, Swelling, MRI, Society, Boston Medical Center, Radiation, Education, Medical imaging, Pharmaceutical industry, Medical device, Black, Alzheimer's disease, Boston

Previous studies have shown that Black patients are at increased risk of Alzheimer's disease and other types of dementia.

Key Points: 
  • Previous studies have shown that Black patients are at increased risk of Alzheimer's disease and other types of dementia.
  • They are less likely to have a diagnosis and are diagnosed at a more advanced stage of disease compared to white patients.
  • Only 50.9% of Black patients underwent MRI testing for cognitive impairment, compared to 60% of white patients, 67% of Hispanics and 68.2% in the Other group.
  • "First, Black patients who received MRI or CT for cognitive impairment were significantly older than patients from other races.

The American Board of Oral and Maxillofacial Surgery Welcomes New President for 2023-2024

Retrieved on: 
Tuesday, November 21, 2023
Examination, Oral and maxillofacial surgery, Surgeon, Boston Medical Center, FACS, Commission, Growth, Certification, Publication, Dentistry, DMD, President (corporate title), Medical device, MD

CHICAGO, Nov. 21, 2023 /PRNewswire/ -- The American Board of Oral and Maxillofacial Surgery (ABOMS) recognizes the service of Immediate Past President, Bernard J. Costello DMD, MD, FACS and welcomes President Pushkar Mehra, DMD, MS, FACS to the head of the organization.

Key Points: 
  • ABOMS welcomes Dr. Pushkar Mehra and recognizes the contributions of Immediate Past President Dr. Bernard Costello
    CHICAGO, Nov. 21, 2023 /PRNewswire/ -- The American Board of Oral and Maxillofacial Surgery (ABOMS) recognizes the service of Immediate Past President, Bernard J. Costello DMD, MD, FACS and welcomes President Pushkar Mehra, DMD, MS, FACS to the head of the organization.
  • Taking the reins from Dr. Costello is Dr. Pushkar Mehra, who is Chief of Oral and Maxillofacial Surgery at Boston Medical Center and both a Professor and the Chair of Oral and Maxillofacial Surgery at the Boston University Henry M. Goldman School of Dental Medicine.
  • He has held leadership positions at the Commission on Dental Accreditation and the Massachusetts Society of Oral and Maxillofacial Surgeons, in addition to his seven years on the ABOMS Board of Directors.
  • "Working with the outstanding Board members and staff we have in our organization, I am confident we will continue to elevate the specialty of Oral and Maxillofacial Surgery."